peripheral blood mononuclear cells (PBMNC) was measured by flow cytometry. CD 80 (B7.1) molecule expression was also measured to investigate the co-signalling capacity of these cells. The results were then compared with clinical events.
MATERIALS AND METHODS
Patients. We studied bone marrow donor alloreactivity to the antigens of 19 patients. These patients were allografted at our centre between 1989 and 1996. The median age at transplant was 45 years (range 24-59); donor median age was 38 (range 30-46). Donors were HLA-identical siblings (17) or volunteer unrelated donors (two). Diagnoses were severe aplastic anaemia (one), acute lymphoblastic leukaemia (two), chronic lymphocytic leukaemia (two), acute myeloid leukaemia (one), chronic myeloid leukaemia (five), non-Hodgkin's lymphoma (four), myelodysplastic syndrome (one) and multiple myeloma (three). Four patients had advanced disease (later than first remission or acute-phase CML) and 15 had standard-risk disease (first complete remission or first chronic phase). None of the grafts was Tcell depleted. Conditioning regimen before BMT and other patient characteristics are shown in Table I . Acute GVHD was graded according to established criteria (Przepiorka et al, 1995) .
HLA typing. Class I HLA molecules were serologically determined for all donor-recipient pairs. Class II molecules or genes were typed with the following methods: serology (patients 3, 5, 8, 15, 16 and 18) ; PCR-RFLP (patients 1, 3, 9, 14, 15, 17 and 18) ; reverse dot blot (patients 1, 2, 4, 6, 10, 11, 12, 13, 16 and 19) , and PCR-SSP (patients 6, 10, 11, 12, 16, 18 and 19) . For 10 patients a combination of several of these methods was necessary to reach a high resolution typing. For patients 5 and 8, class II HLA molecules were typed only by serology. Patient 3 had a HLA-DR 6 allelic difference with his unrelated donor detected by RFLP.
Harvesting and cryopreservation of donor and patient PBMNC. Heparinized or citrated blood from patients and their bone marrow donor was harvested within the 2 weeks preceding BMT, separated on Ficoll-Hypaque (density ¼ 1·077, International Medical, Belgium), washed three times in RPMI 1640 medium (Gibco) and cryopreserved in liquid nitrogen at 5 × 10 6 cells/ml in RPMI 1640 containing 20% heat-inactivated normal AB human pooled serum, glutamin (1·5 mM), penicillin (50 U/ml), streptomycin (50 mg/ml), gentamycin (500 mg/ml) (all from Gibco) and 10% dimethylsulphoxide (Merck, Belgium).
Maintenance of IL-2-sensitive cell line A9.12. The A9.12 cell line was cultivated in RPMI 1640 supplemented with 10% heat-inactivated fetal calf serum (Gibco), glutamine (1·5 mM), hepes buffer (10 mM), sodium pyruvate (2 mM), 2-mercaptoethanol (5 × 10 ¹5 M), penicillin (50 U/ml), streptomycin (50 mg/ml), and gentamycin (500 mg/ml). Recombinant human IL-2 (Eurocetus) was added to reach a final concentration of 100 IU/ml. Cells were divided every 2 or 3 d Conditioning: 1 ¼ total body irradiation 800 cGy þ cyclophosphamide; 2 ¼ total body irradiation 1000 cGy þ cyclophosphamide; 3 ¼ total body irradiation 800 cGy þ high-dose melphalan; 4 ¼ ATG þ cyclophosphamide; 5¼ busulphan þ cyclophosphamide. All patients received cyclosporin A and methotrexate as GVHD prophylaxis. Diagnoses: ALL: acute lymphoblastic leukaemia; AML: acute myeloid leukaemia; CLL: chronic lymphocytic leukaemia; CML: chronic myeloid leukaemia; MDS: myelodysplastic syndrome; MM: multiple myeloma; NHL: nonHodgkin's lymphoma; SAA: severe aplastic anaemia. (s): standard risk (first chronic phase or first complete remission); (a): advanced risk (CML in accelerated or blastic phase, second or later remission). Donor type: MUD ¼ matched unrelated donor; ID ¼ identical sibling donor. and were not allowed to exceed the maximal concentration of 4 × 10 5 cells/ml (Shih et al, 1983) . This cell line was kept in a humidified atmosphere with 5% CO 2 at 37ЊC. They were used to detect IL-2 in HTLp supernatants 2 or 3 d after the last culture to avoid an elevated background.
Limiting dilution assay for HTLp frequency determination. IL-2 secretion from donor lymphocytes was evaluated after in vitro stimulation with patient peripheral blood mononucleated cells (PBMNC). All cells used in the HTLp assay were thawed on the test day and washed three times. Responding cells from the donor were diluted to obtain a final concentration of 8 × 10 4 cells/well/100 ml. These cells were plated in round-bottom plates and serially two-fold diluted with the last dilution at 2·5 × 10 3 cells/well. Stimulating cells from the patient were irradiated (20 Gy; rate 29·6 Gy/min, source of g radiation 137 Cs) and 10 5 cells in 100 ml were added to responding cells. 24 replicates of each dilution were set up. The following controls were set up: 24 wells with stimulating cells alone for determination of positivity threshold and 16 replicates with responding cells alone. The stimulating capacity of patient cells was evaluated with 16 wells containing responding cells from two unrelated HLA-mismatched healthy volunteer controls. The responding capacity of donor cells was evaluated with the same controls irradiated to serve as stimulating cells. Autologous IL-2 secretion was evaluated by culturing 16 replicates of donor or recipient PBMNC with autologous irradiated cells.
The cultures were kept in DMEM supplemented with 10% heat-inactivated normal AB human pooled serum, glutamine (1·5 mM), penicillin (50 U/ml), streptomycin (50 mg/ml) and gentamycin (500 mg/ml), in a humidified atmosphere with 5% CO 2 at 37ЊC for 72 h. After 72 h, 100 ml of the supernatant were transferred to new flat-bottom plates and frozen at ¹70ЊC until further analysis.
On the day of analysis, plates containing supernatants were slowly thawed (4ЊC for 6 h, 37ЊC for 30 min). IL-2 growth dependent cells (A9.12 murine cell line) were washed three times in 50 ml culture medium and starved of IL-2 for 4-6 h. They were diluted in an enriched medium (normal culture medium supplemented with 7 mM sodium pyruvate and 3 mM 2-mercaptoethanol) to obtain a final concentration of 8 × 10 4 cells/ml. 50 ml of this solution were then added to HTLp supernatants. To assess A9.12 cells responsiveness to IL-2 they were incubated in a distinct culture plate with known amounts of rhIL-2, the concentration of which ranged from 0 to 100 IU/ml.
Culture plates were incubated in an humidified atmosphere, 5% CO 2 at 37ЊC for 42 h with the last 18 h in the presence of 3 H-thymidine (74 kBq/well). Thymidine incorporation was measured by harvesting cells to filters and counting b radiation with a b scintillation counter (Beckman LS 6000 SE or Topcount, Packard Instruments). When HLA-mismatched controls were negative for IL-2 secretion, the test was considered as invalid and not included in this study.
Antibodies. Monoclonal mouse antibodies of the following specificity were used: HLA-DR (clone B-F1, FITC labelled, from Serotec), CD 80 (clone L307.4, PE labelled, from Becton Dickinson), mouse IgG1 (FITC or PE labelled, from Becton Dickinson).
Immunofluorescence staining. On the day that the limiting (Taswell, 1984) . The result was calculated using the GLIM software (NAG Ltd, Oxford, U.K.). P values >0·1 were considered as fitting the single hit kinetic from Poisson model.
In HTLp tests the threshold of positivity for IL-2 secretion was obtained from A9.12 proliferation observed in the 24 replicates set up without responder cells as follows: percentile 75 þ (percentile 75 ¹ percentile 25) (Barnett et al, 1984) .
Comparison between median frequency obtained in different subgroups of patients was evaluated using the Mann-Whitney test. Disease-free survival probability was estimated according to Kaplan & Meier (1958) . The relationship between donor sex or disease and GVHD occurrence or survival was tested with Fisher's exact test or with the chi-square test.
RESULTS

HTLp frequency as a predictive test for GVHD occurrence
Donor anti-host HTLp frequency estimation was obtained for 19 patients (Table II) . The median frequency was 1/99031 (range 1/14487 to 1/414621). HTLp frequency was compared with acute GVHD occurrence, donor and patient CMV previous infection and survival. A statistically significant difference was observed between patients with or without acute GVHD grade II-IV (median 1/55848 v 1/ 184346; P ¼ 0·008), and between long-term survivors and deceased patients (median 1/143354 versus 1/22100; P < 0·001). We also observed a trend to significance when CMV-posititve patients had a seronegative donor (median 1/ 79244 v 1/276457 for pairs with both patient and donor seropositive for CMV; P ¼ 0·09). We also correlated disease stage (standard or advanced) and donor sex with GVHD incidence, overal outcome and HTLp test positivity and we did not find any significant correlation. These comparisons are summarized in Table III .
HTLp test was considered positive when more than one donor IL-2 secreting lymphocyte among 150 000 PBMNC could be detected. The test showed 82% sensitivity, 63% specificity, 75% positive predictive value and 71% negative predictive value. When donor HTLp frequency was compared with survival, we found 83% sensitivity and 85% negative predictive value. Therefore this test could also predict post-transplantation survival. In this series of patients probability of disease-free survival was 0·57.
HLA-DR and CD 80 expression by stimulating cells
In 16 patients' PBMNC, HLA-DR and CD 80 expression was 2·5  14487  12  13·6  0·46  15270  18  7·34  1·21  38903  11  23·5  7  54505  15  67·7  1·5  55848  17  10  0·16  65113  10  5·34  2·7  74657  7  38·2  4·3  99031  5  46  3  118698  16  27·5  9  124877  8  50·5  0·8  161831  14  31  0·4  206860  2  14·1  0·8  277311  19  11·4  0·7  311956  13  37·5  0·6  412343  6  22  1·1  414621 measured by flow cytometry to assess the antigen presentation and co-signalling capacity of stimulating cells. We observed a wide range of percentages of positive cells for these two molecules (HLA-DR: median 22·7, range 67·7-5·3; CD 80: median 1·1, range 9-0·16) (Table IV) . No correlation was found between HTLp frequency and HLA-DR or CD80 expression (Fig 1) ; correlation coefficients were 0·0021 and 0·0881 respectively.
DISCUSSION
Donor pretransplant HTLp frequency was performed using an established protocol with minor modifications (Schwarer et al, 1993) in 19 patients who received allogeneic BMT. The first modification was the choice of IL-2-dependent cell line for the revelation of secreted IL-2 in HTLp tests. The A9.12 murine cell line was compared with the more usual CTLL-2 cell line. It was found to be more sensitive and reliable for recombinant IL-2 detection and for HTLp supernatant screening (Winandy et al, 1998) . Other investigators also have chosen this cell line for the same reasons (Lewalle et al, 1996; Keever-Taylor et al, 1997) . However, this cell line sometimes gave a positive signal in negative control wells (containing only stimulating cells) in HTLp tests. These positive values may be explained by IL-2 secretion by stimulating cells, as reported by other investigators (Hornick et al, 1996; Reiseater et al, 1996) . Therefore the positivity threshold for determining IL-2-positive wells had to take these outlying values into account. The threshold was obtained as follows: percentile 75 þ (percentile 75 ¹ percentile 25) from the 24 negative control culture wells. This method enabled the positivity threshold to be based on the median value from negative control wells, and was less influenced by the outlying values than the more classical method (mean þ 3 standard deviations) (Barnett et al, 1984) .
Some authors considered the HTLp test positive when they detected more than one IL-2 secreting T cell in 100 000 PBMNC (Theobald et al, 1992; Schwarer et al, 1993 Schwarer et al, , 1994 . We lowered this threshold because the majority of our patients had a related donor, with genetical HLA identity, and probably closer identity for minor antigens than might be the case in unrelated donor-recipient pairs. In these conditions donor lymphocytes showed a lower IL-2 secretion. This was confirmed by our observation of seven unrelated and three related HLA-identical healthy controls. Median HTLp frequency was 1/104700 and 1/189500, respectively. This observation outlined the importance of non-HLA antigenic disparities. The majority of GVHD patients from this series had a pretransplant HTLp frequency >1/150000 PBMNC, probably reflecting a higher minor antigen disparity degree between donor and recipient. The test results were closely related with GVHD and survival, as shown previously (Theobald et al, 1992; Schwarer et al, 1993 Schwarer et al, , 1994 . However, we observed a lack in outcome prediction for patient 6 whose HTLp test was negative, but who died as a consequence of aGVHD grade III and infectious complications. This fatal outcome may be explained by the fact that multiple myeloma patients generally have a greater risk for post-transplant complications.
There was also a trend to an increased HTLp frequency for CMV seropositive patients with a seronegative donor. It is known that this virus induces the expression of viral antigens on host cells that may constitute minor antigens (Boström et al, 1992; Appleton & Sviland, 1993; Appleton et al, 1995) . This trend for increasing HTLp frequency in CMV-positive recipients confirms the importance of such antigens as stimulating allogeneic responses. We did not find any correlation between disease stage or donor sex with the incidence of acute GVHD, nor with a favourable outcome after transplantation.
Enumeration of cytotoxic T lymphocytes precursors (CTLp) has been shown to be related to acute GVHD occurrence and survival by several groups (Kaminski et al, 1989; Potolicchio et al, 1996; Speiser et al, 1996; KeeverTaylor et al, 1997) . High CTLp frequencies were tightly related to HLA class I mismatches and high HTLp frequencies with class II mismatches (DRB1 or DPB1 alleles). It has to be outlined that the association was made with GVHD grade III-IV and not with grade II-IV. Grade II is generally improved with corticosteroids but may cause important morbidity. It seems important to try to predict also grade II GVHD. Taken together, the data about CTLp and HTLp frequencies are useful as functional in vitro tests, related to HLA and non-HLA antigenic disparities. Helper T lymphocytes act in the afferent branch of GVHD and cytotoxic T lymphocytes in the efferent branch (Theobald, 1995) .
Investigations were made to assess stimulating capacity of patient's PBMNC by analysing HLA-DR and CD80 expression by flow cytometry. These two molecules are essential for antigen presentation and T-cell stimulation. CD80 and CD87 have been shown to be essential for the development of in vitro allogeneic T-cell responses (Knulst et al, 1994; Van Gool et al, 1994; Gribben et al, 1996) . These two molecules being highly inducible on lymphocytes by antigenic or lymphokine stimulation, the question was whether their expression level could influence IL-2 secretion revealed by the HTLp test. None of these parameters was related to pretransplant HTLp frequency. Our results show a wide range of individual HLA-DR expression. This may be explained by the lymphocyte to monocyte ratio, which was low in some samples. CD80 expression was low, as expected for resting lymphocytes. These observations allowed us to consider our samples as homogenous regarding allogeneic stimulating capacity, and the elevated values for HTLp were therefore due to true antigenic stimulation. CD80 and HLA-DR expression as assayed here will evaluate the sample as a whole and will miss infrequent cells which express these molecules strongly. The lack of correlation of expression in the whole sample with HTLp frequency does therefore not mean that there would be no correlation with CD80 and HLA-DR expression by a rare population of stimulating cells.
In conclusion, we confirm that the HTLp test is a suitable tool to detect antigenic differences between HLA-matched donor and patient. It may help in donor selection and prophylactic strategy because it is useful in detecting high risk patients for acute GVHD and post-transplant mortality.
